Prognostic Significance of HPV and p16 Status in Men Diagnosed with Penile Cancer: A Systematic Review and Meta-analysis
| Autor: | Marie Frederiksen, Freja Lærke Sand, Susanne K. Kjaer, Christina Louise Rasmussen, Klaus Kaae Andersen |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
Oncology medicine.medical_specialty Epidemiology 030232 urology & nephrology MEDLINE 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Overall survival Humans Penile cancer Papillomaviridae Penile Neoplasms Cyclin-Dependent Kinase Inhibitor p16 business.industry Cancer Prognosis medicine.disease Optimal management Confidence interval Hpv testing 030220 oncology & carcinogenesis Meta-analysis business |
| Zdroj: | Cancer Epidemiology, Biomarkers & Prevention. 27:1123-1132 |
| ISSN: | 1538-7755 1055-9965 |
| DOI: | 10.1158/1055-9965.epi-18-0322 |
| Popis: | It has been shown that human papillomavirus (HPV) and p16 status has prognostic value in some HPV-associated cancers. However, studies examining survival in men with penile cancer according to HPV or p16 status are often inconclusive, mainly because of small study populations. The aim of this systematic review and meta-analysis was to examine the association between HPV DNA and p16 status and survival in men diagnosed with penile cancer. Multiple electronic databases were searched. Twenty studies were ultimately included and study-specific and pooled HRs of overall survival and disease-specific survival (DSS) were calculated using a fixed effects model. In the analysis of DSS, we included 649 men with penile cancer tested for HPV (27% were HPV-positive) and 404 men tested for p16 expression (47% were p16-positive). The pooled HRHPV of DSS was 0.61 [95% confidence interval (CI), 0.38–0.98], and the pooled HRp16 of DSS was 0.45 (95% CI, 0.30–0.69). In conclusion, men with HPV or p16-positive penile cancer have a significantly more favorable DSS compared with men with HPV or p16-negative penile cancer. These findings point to the possible clinical value of HPV and p16 testing when planning the most optimal management and follow-up strategy. Cancer Epidemiol Biomarkers Prev; 27(10); 1123–32. ©2018 AACR. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|